游离HPV-DNA监测头颈鳞癌治疗反应
合并敏感度0.65(95%CI 0.40-0.84),特异度0.99(99%CI 0.96-0.99),阳性似然比62.5,阴性似然比0.05,诊断比值比371.66。cfHPV-DNA特异度高,可作为PET-CT阳性时的潜在确认试验。
要点
- cfHPV-DNA合并敏感度0.65,特异度0.99,特异度极高。
- 阳性似然比62.5,阴性似然比0.05,诊断比值比371.66。
- 可作为PET-CT阳性时的潜在确认试验,尚需更大样本验证。
核心结论
- cfHPV-DNA特异度极高,可作为PET-CT阳性时HPV阳性头颈鳞癌的潜在确认试验。
- 未来可能作为降阶治疗或免疫治疗临床试验中监测治疗反应的生物标志物。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Scopus三个数据库(2021年1月)。
主要发现
- cfHPV-DNA合并敏感度0.65(95%CI 0.40-0.84),合并特异度0.99(99%CI 0.96-0.99)。
- 阳性似然比62.5(99%CI 22.9-170.2),阴性似然比0.05(99%CI 0.013-0.24)。
- 合并诊断比值比371.66(99%CI 60.4-2286.7)。
关键数值与推荐
- 合并敏感度0.65(95%CI 0.40-0.84),合并特异度0.99(99%CI 0.96-0.99)。
- 阳性似然比62.5(99%CI 22.9-170.2),阴性似然比0.05(99%CI 0.013-0.24)。
- 合并诊断比值比371.66(99%CI 60.4-2286.7)。
临床怎么用
- 目前头颈鳞癌随访方案包括常规临床评估和影像学检查,尚缺乏已建立的监测生物标志物。
- 鉴于cfHPV-DNA高特异度,可考虑在PET-CT阳性时作为确认试验。
- 在降阶治疗或免疫治疗临床试验中,cfHPV-DNA或可用于监测治疗反应。
局限性
- 需要更大样本量以及研究方案和方法学的同质化,以更好确立其在临床实践中的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: The aim of this study was to assess the value of cell-free human papillomavirus-DNA (cfHPV-DNA) as a diagnostic test for the post-treatment surveillance of patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) through a systematic review and meta-analysis. STUDY DESIGN: Systematic review and meta-analysis. METHODS: A literature search was conducted in three databases (MEDLINE, Embase, and Scopus) in January 2021. The population included patients with HPV-positive HNSCC. The intervention was the use of the repeated liquid biopsy with circulating HPV-DNA detection during follow-up. The outcome was to establish the value of cfHPV-DNA as a diagnostic test for the post-treatment surveillance of patients with HPV-positive HNSCC. RESULTS: Ten studies included in the meta-analysis provided a total of 457 patients with HPV-positive HNSCC. The meta-analytic study estimated the diagnostic performance of cfHPV-DNA as follows: pooled sensitivity and specificity of 0.65 (95% confidence interval [CI]: 0.40-0.84) and 0.99 (99% CI: 0.96-0.99), respectively; positive and negative likelihood ratios of 62.5 (99% CI: 22.9-170.2) and 0.05 (99% CI: 0.013-0.24), respectively; and pooled diagnostic odds ratio of 371.66 (99% CI: 60.4-2286.7). CONCLUSION: Currently, the follow-up protocol for HNSCC patients includes routine clinical evaluation and radiological imaging. Biomarkers to monitor this disease are not established. Considering its high specificity, cfHPV-DNA represents a potential confirmatory test in the case of positive positron emission tomography and computed tomography. In the near future, cfHPV-DNA could be used as a biomarker for monitoring the treatment response during the clinical trials of de-escalation therapy or immunotherapy. Larger sample sizes and the homologation of study protocols and methodology are needed to better establish its utility in the clinical practice. Laryngoscope, 132:560-568, 2022.
引用
- Campo F, Zocchi J, Moretto S, et al. Cell-Free Human Papillomavirus-DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. Laryngoscope. 2021. PMID: 34236084. doi:10.1002/lary.29739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。